Ovarian Endometrioid Adenocarcinoma Completed Phase 2 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerTreatment